1. CD47–SIRPα-targeted therapeutics: status and prospects. (March 2022) Authors: Maute, R.; Xu, J.; Weissman, I.L. Journal: Immuno-oncology technology Issue: Volume 13(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS). (23rd June 2022) Authors: Chen, J. Y.; Johnson, L.; McKenna, K. M.; Choi, T. S.; Duan, J.; Feng, D.; Tsai, J. M.; Garcia-Martin, N.; Sompalli, K.; Maute, R.; Vyas, P.; Majeti, R.; Takimoto, C. H. M.; Liu, J.; Ramsingh, G.; Chao, M. P.; Volkmer, J.-P.; Weissman, I. L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 635 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗